Newer agents for hormonal contraception in the male

Trends in Endocrinology and Metabolism

Volumn 11, Issue 2, 2000, Pages 61-66

  Amory, John K ^a   Bremner, William J ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; CYPROTERONE ACETATE; DESOGESTREL; GESTAGEN; GONADORELIN DERIVATIVE; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; NANDROLONE DERIVATIVE; TESTOSTERONE; TESTOSTERONE ENANTATE; TESTOSTERONE UNDECANOATE;

AZOOSPERMIA; GONADOTROPIN RELEASE; HORMONAL CONTRACEPTION; HORMONE ACTION; HORMONE STRUCTURE; HUMAN; MALE; OLIGOSPERMIA; PRIORITY JOURNAL; REVIEW; SPERMATOGENESIS;

ANDROGENS; CONTRACEPTION; CONTRACEPTIVE AGENTS, MALE; DRUG SYNERGISM; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; PROGESTINS; TESTOSTERONE;

EID: 0034159947     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1043-2760(99)00224-6     Document Type: Review

References (37)

1. Amory J.K., Bremner W.J. The use of testosterone as a male contraceptive. Bailliere's Clin. Endocrinol. Metab. 12:1998;471-484.
2. World Health Organization Task Force on Methods for the Regulation of Male Fertility Contraceptive efficacy of testosterone-induced azoospermia and oligozoospermia in normal men. Fertil. Steril. 65:1996;821-829.
3. Handelsman D.J.et al. Factors in nonuniform induction of azoospermia by testosterone enanthate in normal men. Fertil. Steril. 63:1995;125-133.
4. Bagatell C.J., Bremner W.J. Androgens in men - uses and abuses. New Engl. J. Med. 334:1996;707-714.
5. World Health Organization Contraceptive efficacy of testosterone-induced azoospermia in normal men. Lancet. 336:1990;995-999.
6. Bagatell C.J.et al. Metabolic and behavioral effects of high-dose, exogenous testosterone in healthy men. J. Clin. Endocrinol. Metab. 79:1994;561-567.
7. Meriggiola M.C.et al. Testosterone enanthate at the dose 200 mg/week decreases HDL-cholesterol levels in healthy men. Int. J. Androl. 18:1995;237-242.
8. Behre H.M., Nieschlag E. Testosterone buciclate (20 Aet-1) in hypogonadal men: pharmacokinetics and pharmacodynamics of the new long-acting androgen ester. J. Clin. Endocrinol. Metab. 75:1992;1204-1210.
9. Coert A.et al. The pharmacology and metabolism of testosterone undecanoate (TU), a new orally active androgen. Acta Endocrinol. 79:1975;789-800.
10. Zhang G.Y.et al. A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men. J. Androl. 19:1998;761-768.
11. Behre A.M.et al. Intramuscular injection of testosterone undecanoate for the treatment of male hypogonadism: phase I studies. Eur. J. Endrocrinol. 140:1999;414-419.
12. Zhang G.Y.et al. Injectable testosterone undecanoate for contraception in Chinese men. J. Clin. Endocrinol. Metab. 84:1999;3642-3647.
13. Schurmeyer T.et al. Reversible azoospermia induced by the anabolic steroid 19-nortestosterone. Lancet. 25:1984;417-420.
14. World Health Organization Comparison of two androgens plus depot-medroxyprogesterone acetate for suppression to azoospermia in Indonesian men. Fertil. Steril. 60:1993;1062-1068.
15. Sundaram K.et al. 7-alpha-methyl-19-nortestosterone: an ideal androgen for replacement therapy. Recent Prog. Horm. Res. 49:1994;373-376.
16. Anderson R.et al. Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. III. Higher 5α-reductase activity in oligospermic men administered supraphysiological doses of testosterone. J. Clin. Endocrinol. Metab. 81:1996;902-908.
17. Cummings D.E.et al. Prostate-sparing tissue specific effects of the potent androgen 7α-methyl-19-nortestosterone (MENT) in primates. J. Clin. Endocrinol. Metab. 83:1998;4212-4219.
18. Buchter D.et al. Clinical trial of transdermal testosterone and oral levonorgestrel for male contraception. J. Clin. Endocrinol. Metab. 84:1999;1244-1249.
19. Hamann L.G.et al. Discovery of a potent, orally active, nonsteroidal androgen receptor agonist: 4-ethyl-1,2,3,4-tetrahydro-6-(trifluoromethyl)-8-pyri-dono[5,6-g]-quinoline (LG121071). J. Med. Chem. 42:1999;210-212.
20. Pavlou S.N.et al. Combined administration of a gonadotropin-releasing hormone antagonist and testosterone in men induces reversible azoospermia without loss of libido. J. Clin. Endocrinol. Metab. 73:1991;1360-1369.
21. Tom L.et al. Induction of azoospermia in normal men with combined Nal-Glu gonadotropin-releasing hormone and testosterone enanthate. J. Clin Endocrinol. Metab. 75:1992;476-483.
22. Bagatell C.J.et al. Comparison of a gonadotropin releasing-hormone antagonist plus testosterone (T) versus T alone as potential male contraceptive regimens. J. Clin. Endocrinol. Metab. 77:1993;427-432.
23. Swerdloff R.S.et al. Suppression of spermatogenesis in man induced by Nal-Glu gonadotropin releasing hormone antagonist and testosterone enanthate (TE) is maintained by TE alone. J. Clin. Endocrinol. Metab. 83:1998;3527-3533.
24. Yeung C.H.et al. Effect of acute androgen withdrawal by GnRH antagonist on epididymal sperm motility and morphology in the cynomolgus monkey. J. Androl. 20:1999;72-79.
25. Rolf C.et al. Pharmacokinetics of new testosterone transdermal therapeutic systems in gonadotropin-releasing hormone antagonist-suppressed normal men. Exp. Clin. Endocrinol. Diabetes. 107:1999;63-69.
26. Cho N.et al. Discovery of a novel, potent and orally active nonpeptide antagonist of the human luteinizing hormone-releasing hormone (LHRH) receptor. J. Med. Chem. 41:1998;4190-4195.
27. Schearer S.B.et al. Hormonal contraception for men. Int. J. Androl. 2:1978;680-695.
28. Fotherby K.et al. Effect of low doses of synthetic progestogens on testicular function. Int. J. Fertil. 17:1972;113-119.
29. Meriggiola M.C., Bremner W.J. Progestin-androgen combination regimens for male contraception. J. Androl. 18:1997;240-244.
30. Barfield A.et al. Pregnancies associated with sperm concentrations below 10 million/ml in clinical studies of a potential male contraceptive method, monthly depot medroxyprogesterone acetate and testosterone esters. Contraception. 20:1977;121-127.
31. Bebb R.A.et al. Combined administration of levonorgestrel and testosterone induces more rapid and effective suppression of spermatogenesis than testosterone alone: a promising male contraceptive approach. J. Clin. Endocrinol. Metab. 81:1996;757-762.
32. Anawalt B.D.et al. A lower dosage levonorgestrel and testosterone combination effectively suppresses spermatogenesis and circulating gonadotropin levels with fewer metabolic effects than higher dosage combinations. J. Androl. 20:1999;407-414.
33. Wu F.C.et al. Oral progestogen combined with testosterone as a potential male contraceptive: additive effects between desogestrel and testosterone enanthate in suppression of spermatogenesis, pituitary-testicular axis, and lipid metabolism. J. Clin. Endocrinol. Metab. 84:1999;112-122.
34. Neumann F., Topert M. Pharmacology of antiandrogens. J. Steroid Biochem. 25:1986;885-895.
35. Meriggiola M.C.et al. A combined regimen of cyproterone acetate and testosterone enanthate as a potentially highly effective male contraceptive. J. Clin. Endocrinol. Metab. 81:1996;3018-3023.
36. Meriggiola M.C.et al. Low dose of cyproterone acetate and testosterone enanthate for contraception in men. Hum. Reprod. 13:1998;1225-1229.
37. Meriggiola M.et al. An oral regimen of cyproterone acetate and testosterone for spermatogenic suppression in men. Fertil. Steril. 68:1997;844-850.